Polyclonal Anti-NFκBP65 **(Sepharose Bead Conjugate)**

Catalogue No. PA11225-S

Lot No. 08J01

Ig type: rabbit IgG

Size: 100μg/vial

Specificity

Human.
No cross reactivity
with other proteins.

Recommended application

(Immunoprecipitation(IP)

Immunogen

A synthetic peptide mapping at the N-terminal of human NFκBP65, identical to the related rat and mouse sequence.

Purification

Immunogen affinity purified.

Formulation

50% slurry in PBS pH 7.2 with 0.01mg NaN_3a_3 preservative.

Storage

Store at 4˚C for frequent use.

Description:

This Antagene antibody is immobilized via covalent binding of primary amino groups to N-hydroxysuccinimide (NHS)-activated sepharose beads. It is useful for immunoprecipitation assays

BACKGROUND

The p65 (RELA) heterodimer is the most abundant form of NFKB. This gene is located on 11q13, which consists of 10 exons and spans about 8.1 kb of DNA1. In rat sciatic nerves, the expression of the activated p65 subunit of NFKB was high in the nuclei of premyelinating Schwann cells and then progressively declined until it was nearly absent in adults2. The transcriptional activity of NF-kappa-B is stimulated upon phosphorylation of its p65 subunit on serine-276 by protein kinase A (PKA). The transcriptional coactivator CBP /p300 associates with NF-kappa-B p65 through 2 sites, an N-terminal domain that interacts with the C-terminal region of unphosphorylated p65, and a second domain that only interacts with p65 phosphorylated on serine-2763.

REFERENCE

1. Deloukas, P.; van Loon, A. P. G. M. : Genomic organization of the gene encoding the p65 subunit of NF-kappa-B: multiple variants of the p65 protein may be generated by alternative splicing. Hum. Molec. Genet. 2: 1895-1900, 1993.
2. Nickols, J. C.; Valentine, W.; Kanwal, S.; Carter, B. D. : Activation of the transcription factor NF-kappa-B in Schwann cells is required for peripheral myelin formation. Nature Neurosci. 6: 161-167, 2003.
3. Zhong, H.; Voll, R. E.; Ghosh, S. : Phosphorylation of NF-kappa B by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. *Molec. Cell* 1: 661-671, 1998.

Contact: Antagene, Inc. | Tel: 1 (866) 964-2589 | Fax: 1 (888) 225-1868 | Email:Info@antageneinc.com